Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
EPS Growth %: +30.8%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43.4 million versus the consensus estimate of $25.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
